Harry J. Long

6.5k citations

95 papers · 4.8k indexed · 1 hit paper · h-index 36

Impact in

Obstetrics and Gynecology top 0.1%
- Endometrial and Cervical Cancer Treatments
- Uterine Myomas and Treatments
Reproductive Medicine top 0.5%
- Ovarian cancer diagnosis and treatment

Papers in

Obstetrics and Gynecology 43
- Endometrial and Cervical Cancer Treatments 41
Reproductive Medicine 30
- Ovarian cancer diagnosis and treatment 27

Co-authors: Bradley J. Monk Helen Huang Mario M. Leitão Krishnansu S. Tewari Lisa M. Landrum Thomas Reid Ana Oaknin Lois M. Ramondetta
Journals: Gynecologic Oncology (20 papers)Journal of Clinical Oncology (19 papers)Cancer (13 papers)Mayo Clinic Proceedings (4 papers)Investigational New Drugs (2 papers)
Partner nations: United States Spain Canada

In The Last Decade

Harry J. Long

94 papers receiving 4.6k citations

Hit Papers

align trajectories log scale

Improved Survival with Bevacizumab in Advanced Cervical Cancer 2014 · 1.0k citations

Peers

Countries citing papers authored by Harry J. Long

Since Specialization

Citations

This map shows the geographic impact of Harry J. Long's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry J. Long with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry J. Long more than expected).

Fields of papers citing papers by Harry J. Long

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry J. Long. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry J. Long. The network helps show where Harry J. Long may publish in the future.

Co-authors

The 25 scholars most cited alongside Harry J. Long, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Harry J. Long Line = papers co-authored together Harry J. Long links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study Clinical Cancer Research ·Krishnansu S. Tewari, Michael W. Sill, Bradley J. Monk, Richard T. Penson, Harry J. Long, Andrés Poveda, Lisa M. Landrum, Mario M. Leitão, Jubilee Brown, Thomas Reid, Cristina América Morando-Grijalva, David H. Moore	2015	53
2	Improved Survival with Bevacizumab in Advanced Cervical Cancer New England Journal of Medicine ·Krishnansu S. Tewari, Michael W. Sill, Harry J. Long, Richard T. Penson, Helen Huang, Lois M. Ramondetta, Lisa M. Landrum, Ana Oaknin, Thomas Reid, Mario M. Leitão, Cristina América Morando-Grijalva, Bradley J. Monk Hit paper breakdown →	2014	1025
3	Quality of life and survival in advanced cervical cancer: A Gynecologic Oncology Group study Gynecologic Oncology ·Dana M. Chase, Helen Huang, Lari Wenzel, David Cella, Richard P. McQuellon, Harry J. Long, David H. Moore, Bradley J. Monk	2012	36
4	Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer Cancer Research ·Evanthia Galanis, Lynn C. Hartmann, William A. Cliby, Harry J. Long, Prema P. Peethambaram, Brigitte A. Barrette, Judith S. Kaur, Paul Haluska, Ileana Aderca, Paula J. Zollman, Jeff A. Sloan, Gary L. Keeney, Philip J. Atherton, Karl C. Podratz, Sean C. Dowdy, C.Robert Stanhope, Timothy O. Wilson, Mark J. Federspiel, Kah-Whye Peng, Stephen J. Russell	2010	252
5	From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer Annals of Oncology ·Giovanni Aletti, Febry Indah Sari, Lynn C. Hartmann, Mary M. Gallenberg, Harry J. Long, William A. Cliby	2010	3
6	Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: A Gynecologic Oncology Group Study Gynecologic Oncology ·David H. Moore, Chunqiao Tian, Bradley J. Monk, Harry J. Long, George Omura, Jeffrey D. Bloss	2009	115
7	A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study Gynecologic Oncology ·Howard D. Homesley, Virginia L. Filiaci, Susan K. Gibbons, Harry J. Long, David Cella, Nick M. Spirtos, Robert Morris, Koen DeGeest, Roger Lee, Anthony Montag	2008	153
8	Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium Gynecologic Oncology ·Harry J. Long, Robert A. Nelimark, Karl C. Podratz, Vera J. Suman, Gary L. Keeney, Daniel A. Nikcevich, John W. Kugler, Kendrith M. Rowland, Carl G. Kardinal, Edward J. Wos	2005	10
9	Long-Term Survival of Patients With Advanced/Recurrent Carcinoma of Cervix and Vagina After Neoadjuvant Treatment With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without the Addition of Molgramostim, and Review of the Literature American Journal of Clinical Oncology ·Harry J. Long, Noé Contreras-Gonz alez, Karl C. Podratz, S N Nakhwa, Vera J. Suman, Lynn C. Hartmann, Ralph Levitt, Suresh Nair, Alan K. Hatfield, James A. Knost	2002	12
10	Second-line and subsequent therapy for ovarian carcinoma Current Oncology Reports ·Prema P. Peethambaram, Harry J. Long	2002	6
11	Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas? Annals of Oncology ·J H Edmonson, Harry J. Long, Larry K. Kvols, Bhupinder Mann, Jacques Grill	1997	11
12	Adjuvant Chemotherapy versus Chemotherapy plus Pelvic Irradiation for High-Risk Cervical Cancer Patients after Radical Hysterectomy and Pelvic Lymphadenectomy (RH-PLND): A Randomized Phase III Trial Gynecologic Oncology ·John P. Curtin, William J. Hoskins, Ennapadam Venkatraman, Lois Almadrones, Karl C. Podratz, Harry J. Long, Michael Teneriello, Hervy E. Averette, Bernd‐Uwe Sevin	1996	71
13	Phase II Trial of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced/Recurrent Carcinoma of the Uterine Cervix and Vagina Gynecologic Oncology ·Harry J. Long, Tamra Beaubouef, H. Samuel Wieand, Reşat AŞTI, Tânia Tiemi Ikeoka, John W. Kugler, Loren K. Tschetter, Carl G. Kardinal, Larry P. Ebbert, Noé Contreras-Gonz alez	1995	30
14	Paclitaxel (Taxol): A Novel Anticancer Chemotherapeutic Drug Mayo Clinic Proceedings ·Harry J. Long	1994	68
15	Granulocyte-macrophage colony-stimulating factor: Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin Cancer ·J H Edmonson, Lynn C. Hartmann, Harry J. Long, Anne-Marie Crown, Tom R. Fitch, John A. Jefferies, Pedro Pablo Pomboza, William J. Maples	1992	26
16	Combination hormonal therapy with tamoxifen plus fluoxymesteroneversus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis Cancer ·James N. Ingle, Harry J. Long, Donald I. Twito, Daniel J. Schaid, Stephen A. Cullinan, Yongfeng HE, James E. Krook, James A. Mailliard, Loren K. Tschetter, Cláudia Rhode, Ralph Levitt, Delano M. Pfeifle	1991	91
17	Phase II evaluation of menogaril in patients with advanced hypernephroma Investigational New Drugs ·Harry J. Long, R Kakim-Murad, Nirja Agasti, Jan C. Buckner, Stephen Frytak, Richard G. Hahn	1991	4
18	Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer. Journal of Clinical Oncology ·James N. Ingle, Donald I. Twito, Daniel J. Schaid, Stephen A. Cullinan, James E. Krook, J A Mailliard, Robert F. Marschke, Harry J. Long, Yongfeng HE, Harold E. Windschitl	1988	23
19	Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion. PubMed ·Harry J. Long, Garth Powis, Atsuko Schütt, C G Moertel	1987	6
20	Systolic time interval recordings as a measure of cardiac function in the healthy rabbit: Reference values American Journal of Veterinary Research ·Harry J. Long, Kaikhusroo M. Jamaspasa, T. J. FIVELAND, 余凡 YU Fan	1982	1

About Harry J. Long

Harry J. Long is a scholar working on Obstetrics and Gynecology, Reproductive Medicine, Oncology, Pulmonary and Respiratory Medicine and Epidemiology, having authored 95 papers that have together received 4.8k indexed citations. Recurring topics across this work include Endometrial and Cervical Cancer Treatments (41 papers), Ovarian cancer diagnosis and treatment (27 papers), Cervical Cancer and HPV Research (13 papers), Cancer Treatment and Pharmacology (13 papers), Colorectal and Anal Carcinomas (10 papers), Immunotherapy and Immune Responses (8 papers), Gastric Cancer Management and Outcomes (6 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). The work is most often cited by research in Obstetrics and Gynecology (2.2k citations), Reproductive Medicine (1.3k citations), Oncology (1.7k citations), Epidemiology (1.1k citations) and Surgery (1.1k citations). Harry J. Long has collaborated with scholars based in United States, Spain and Canada. Frequent co-authors include Bradley J. Monk, Helen Huang, Mario M. Leitão, Krishnansu S. Tewari, Lisa M. Landrum, Thomas Reid, Ana Oaknin, Lois M. Ramondetta, Richard T. Penson and Michael W. Sill. Their work appears in journals such as Gynecologic Oncology, Journal of Clinical Oncology, Cancer, Mayo Clinic Proceedings and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact